CN Patent

CN106632311B — 一种帕博西尼晶型a和晶型b的制备方法

Assigned to Shanghai Kesheng Pharmaceutical Research And Development Co ltd · Expires 2021-05-18 · 5y expired

What this patent protects

本发明公开了一种在水或水和可与水混溶的有机溶剂混合溶剂中制备6‑乙酰基‑8‑环戊基‑5‑甲基‑2‑[[5‑(哌嗪‑1‑基)吡啶‑2‑基]氨基]‑8H‑吡啶并[2,3‑D]嘧啶‑7‑酮游离碱晶型A和晶型B的方法，该方法操作安全便捷，污染小，易于工业化生产。

USPTO Abstract

本发明公开了一种在水或水和可与水混溶的有机溶剂混合溶剂中制备6‑乙酰基‑8‑环戊基‑5‑甲基‑2‑[[5‑(哌嗪‑1‑基)吡啶‑2‑基]氨基]‑8H‑吡啶并[2,3‑D]嘧啶‑7‑酮游离碱晶型A和晶型B的方法，该方法操作安全便捷，污染小，易于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN106632311B
Jurisdiction
CN
Classification
—
Expires
2021-05-18
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Kesheng Pharmaceutical Research And Development Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.